Literature DB >> 17531624

Endometrial effects of intrauterine levonorgestrel.

Anja Guttinger1, Hilary O D Critchley.   

Abstract

Local intrauterine delivery of levonorgestrel (LNG) results in extensive decidualization of endometrial stromal cells, atrophy of the glandular and surface epithelium and changes in vascular morphology (suppression of spiral artery formation and presence of large dilated vessels). With endometrial exposure to LNG, there is down-regulation of sex steroid receptors in all cellular components. As a consequence of endometrial sex steroid receptor down-regulation, there is perturbation of progesterone-regulated locally acting mediators, and the integrity of blood vessel walls is disturbed. Thus, intrauterine LNG administration results in modulation of local mediators regulating endometrial function. To date, no single factor has been identified where the expression correlates closely with unscheduled breakthrough bleeding (BTB). BTB is a common side effect and reason for discontinuation of LNG-IUS use. Much remains to be determined about the mechanisms involved in suppression of menstruation, BTB episodes and the local endometrial environment with local LNG administration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531624     DOI: 10.1016/j.contraception.2007.01.015

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  25 in total

1.  Morphological and Ultrastructural Changes in Human Endometrium Following Low-Dose Levonorgestrel Contraceptive Intrauterine Systems (LNG-IUS-12) 13.5 mg.

Authors:  Minghan Chai; Shili Su; Baihua Dong
Journal:  J Obstet Gynaecol India       Date:  2014-10-29

2.  Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: a randomized controlled trial.

Authors:  Megan A Cohen; Katharine B Simmons; Alison B Edelman; Jeffrey T Jensen
Journal:  Contraception       Date:  2019-06-18       Impact factor: 3.375

3.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

4.  Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix.

Authors:  Gabriel A Goldfien; Fatima Barragan; Joseph Chen; Margaret Takeda; Juan C Irwin; Jean Perry; Ruth M Greenblatt; Karen K Smith-McCune; Linda C Giudice
Journal:  Reprod Sci       Date:  2015-01-28       Impact factor: 3.060

5.  Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial.

Authors:  Tessa Madden; Sarah Proehl; Jenifer E Allsworth; Gina M Secura; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2011-09-24       Impact factor: 8.661

6.  Long-term progestin contraceptives (LTPOC) induce aberrant angiogenesis, oxidative stress and apoptosis in the guinea pig uterus: A model for abnormal uterine bleeding in humans.

Authors:  Graciela Krikun; Irina A Buhimschi; Martha Hickey; Frederick Schatz; Lynn Buchwalder; Charles J Lockwood
Journal:  J Angiogenes Res       Date:  2010-04-27

7.  Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

Authors:  Gabriella Macchia; Francesco Deodato; Savino Cilla; Francesco Legge; Vito Carone; Vito Chiantera; Vincenzo Valentini; Alessio Giuseppe Morganti; Gabriella Ferrandina
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

8.  Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium.

Authors:  M-L Alvarez Gonzalez; C Galant; F Frankenne; M Nisolle; S Labied; J-M Foidart; E Marbaix; A Béliard
Journal:  Hum Reprod       Date:  2008-12-17       Impact factor: 6.918

9.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.